Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Regeneron records the net product sales of Eylea and Eylea HD in ... which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced ...

Image Source: Zacks Investment Research Lead ... Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country.

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Hershey beat fourth-quarter profit and sales estimates as the chocolate maker's price hikes helped offset the higher cost of cocoa.

In the?US, the generic name for Libtayo in its approved?indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for ... amid concerns about the company's primary product, EYLEA, facing competition from Amgen ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks ... This comes amid concerns about the company's primary product, EYLEA, facing ...